eng ita
  • Drug development for neuropsychiatric disorders

    Schizophrenia is associated with alterations in cognitive and emotional functions. For decades scientists and clinicians have made efforts with the aim of discovering an efficacious pharmacological treatment of schizophrenia. However, the complexity of the disorder, due to a wide array of symptoms, has hampered those efforts. There are no specific focal characteristics for the diagnosis of schizophrenia and no single symptom is consistently present in all patients. Consequently, the diagnosis of schizophrenia as a single disorder or as a variety of different disorders has been discussed but not yet resolved. The symptoms can be grouped into positive and negative symptoms. Positive symptoms include altered behaviour, such as delusions, hallucinations, extreme emotions, excited motor activity and incoherent speech. In contrast, negative symptoms are described as a lack of behaviour, such as poverty of speech, social withdrawal, avolition, anhedonia and affective blunting. Cognitive deficits include reduction in working memory, attention and verbal fluency. The major difficulty that scientists and clinicians have to face in the development of a new antipsychotic drug is the lack of knowledge about the underlying cause and nature of the disorder. For this reason, in order to rationalise the development of an antipsychotic therapy, some neurochemical hypotheses have been proposed on the basis of biochemical, pharmacological, imaging and electrophysiological evidence and behavioural studies. Three main hypotheses have emerged: the dopamine, the serotonin and the glutamate hypothesis. NatSynDrugs is actually focusing on the development of drug candidates characterized by a multireceptor affinity profiles with emphasis on the role of

    • • dopamine D2L,S / serotonine 5-HT2A
    • • dopamine D2L,S / dopamine D3 / serotonine 5-HT1A
    • • dopamine D2L,S / metabotropic GluR5

Headquarters: via Banchi di Sotto, 55 - 53100 Siena ITALY
tel. +39 0577.234172 - +39 0577.234297 - fax. +39 0577.234333 - e-mail:info@natsyndrugs.com